Roquefort Therapeutics (LON:COIL) Releases Earnings Results

Roquefort Therapeutics (LON:COIL) released its quarterly earnings results on Monday. The company reported GBX (1.66) EPS for the quarter, Digital Look Earnings reports. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative return on equity of 18.71%.

Roquefort Therapeutics Stock Down 3.5%

Shares of LON COIL opened at GBX 7.24 on Wednesday. The stock has a market capitalization of £30.90 million, a P/E ratio of -0.33 and a beta of 0.05. The stock’s fifty day moving average is GBX 8.86 and its 200 day moving average is GBX 9.29. Roquefort Therapeutics has a 52 week low of GBX 6.75 and a 52 week high of GBX 12.50. The company has a debt-to-equity ratio of 8.18, a quick ratio of 3.07 and a current ratio of 0.63.

Analysts Set New Price Targets

Separately, Shore Capital Group reiterated a “house stock” rating on shares of Roquefort Therapeutics in a research note on Monday, September 21st.

Insider Buying and Selling at Roquefort Therapeutics

In other news, insider Stephen Paul West purchased 261,437 shares of the business’s stock in a transaction dated Monday, September 28th. The stock was bought at an average price of GBX 8 per share, with a total value of £20,914.96. Company insiders own 36.15% of the company’s stock.

About Roquefort Therapeutics

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.